We analyzed the clinicopathological characteristics of recurrent tumors and explored the genomic factors affecting recurrence through gene expression analysis in relapsing and nonrelapsing patients with HER2-positive early breast cancer who received adjuvant trastuzumab. The gene discussed is ERBB2; the disease is breast cancer.